Scientists probe Glucagon's role in liver health and diabetes
NCT ID NCT05500586
First seen Nov 10, 2025 · Last updated Jun 16, 2026 · Updated 33 times
Summary
This study looked at how the hormone glucagon affects the liver's ability to break down proteins and fats in people with obesity, type 2 diabetes, and fatty liver disease. Researchers wanted to understand if the body becomes resistant to glucagon in these conditions. A total of 21 participants completed the study, which involved measuring amino acid clearance with and without glucagon.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.